Arriving in the landscape of obesity therapy, retatrutide represents a unique method. Beyond many current medications, retatrutide works as a double agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) sensors. The dual engagement encourages several beneficial effects, such as en